Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2008
Business Overview: Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference (RNAi). The company has no approved products and generates revenue primarily through strategic alliances, government contracts, and licensing. Key programs include ALN-RSV01 (Phase II for RSV) and various pre-clinical candidates for liver cancer, hypercholesterolemia, and Huntington's disease.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2008) |
|---|---|---|---|
| Net Revenues | $25,734 | $71,759 | N/A |
| Net Loss | $(2,858) | $(16,857) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.41) | N/A |
| Operating Expenses | $28,968 | $91,781 | N/A |
| Cash & Cash Equivalents | N/A | N/A | $196,737 |
| Marketable Securities | N/A | N/A | $323,426 |
| Total Assets | N/A | N/A | $580,181 |
| Total Liabilities | N/A | N/A | $375,624 |
| Stockholders' Equity | N/A | N/A | $204,557 |
| Accumulated Deficit | N/A | N/A | $(242,850) |
Note: Marketable securities include $223,379 current and $100,047 non-current.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased significantly to $25.7 million for the quarter (from $16.3 million in 2007) and $71.8 million for the nine-month period (from $32.7 million in 2007). This was driven by the recognition of revenue from the Roche alliance (effective Aug 2007) and the new Takeda alliance (May 2008).
- Expense Reduction: Total operating expenses decreased by 57% for the quarter and 25% for the nine-month period compared to the prior year. Research and Development (R&D) expenses dropped significantly due to the absence of large one-time license fees paid in the prior year (specifically $27.5 million to Isis related to the Roche deal and $6.0 million for drug delivery activities).
- Net Loss Improvement: Net loss narrowed substantially to $2.9 million for the quarter (from $52.8 million) and $16.9 million for the nine months (from $87.1 million), primarily due to revenue recognition and reduced R&D costs.
- Liquidity: Cash and cash equivalents increased to $196.7 million from $105.2 million at year-end 2007, bolstered by upfront payments from Takeda ($100 million) and Kyowa Hakko ($15 million).
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring net losses for the foreseeable future as R&D activities expand. Future funding is expected to come from strategic alliances (Roche, Takeda, Novartis), government contracts, and potential equity financings.
- Strategic Alliances:
- Takeda: Received $100 million upfront; revenue recognized over 7 years. Additional $50 million in near-term milestones.
- Kyowa Hakko: Received $15 million upfront for exclusive rights to ALN-RSV01 in Asia; revenue deferred until performance period can be estimated.
- Novartis: Extended collaboration term through October 2009.
- Unusual Items:
- Recorded a $1.6 million impairment charge on its investment in Tekmira Pharmaceuticals due to a decline in fair value deemed other than temporary.
- Recorded a $0.9 million credit to income taxes in Q3 2008 to correct an overstatement of state income tax provision in the prior six months.
- Risks:
- Capital Needs: The company requires substantial additional funds to complete R&D and clinical trials. Failure to secure funding could force curtailment of operations.
- Regulatory & Clinical: No products have received regulatory approval. Clinical trials (e.g., ALN-RSV01) carry high risks of failure or delay.
- Collaborator Dependence: Significant reliance on partners (Roche, Takeda, Novartis) for funding and commercialization; termination of these agreements would be materially adverse.
- Intellectual Property: Risks related to patent challenges and the ability to enforce rights in the emerging RNAi field.
Investor Verification Checklist
- Deferred Revenue: Verify the $349.5 million in deferred revenue and the assumptions regarding the recognition periods (5 years for Roche, 7 years for Takeda).
- Cash Burn Rate: Assess the runway provided by the $520.2 million in cash and marketable securities against projected R&D spend and operating costs.
- Clinical Progress: Monitor the results of the ongoing Phase II trial for ALN-RSV01 in lung transplant patients.
- Investment Impairment: Review the valuation methodology for the Tekmira investment and potential for further impairment charges.
- Collaborator Milestones: Track the achievement of technology transfer and development milestones with Takeda and Kyowa Hakko to ensure future cash inflows.